ReviewBone marrow transplantation2014
EBV-induced post transplant lymphoproliferative disorders: a persisting challenge in allogeneic hematopoetic SCT.
Review in Bone marrow transplantation, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 1 synthesis or guideline pooled it, 125 citations in OpenAlex.
- Anti-Thymocyte Globulin Prophylaxis in Patients With Hematological Malignancies Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: An Updated Meta-Analysis.Frontiers in oncology · 2021Pooled it
- A review of bloodstream infections-pathogens, pathogenesis, diagnostic strategies, treatment methods-challenges and future aspects.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Review
- Treatment of post-transplant lymphoproliferative disorders in kidney transplant recipients: a single-center retrospective analysis.International journal of hematology · 2025Article
- A model of lymphocryptovirus-associated post-transplant lymphoproliferative disorder in immunosuppressed Mauritian cynomolgus macaques.PLoS pathogens · 2024Article
- Review
- Cytokine-induced killer cells: new insights for therapy of hematologic malignancies.Stem cell research & therapy · 2024Review
- Analytical and clinical evaluation of the cobas Epstein-Barr virus test at a tertiary care cancer hospital.Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology · 2024Article
- Epstein-Barr virus-positive iris diffuse large B-cell lymphoma detected by metagenomic next-generation sequencing.BMC ophthalmology · 2024Article
- Outcomes for patients with EBV-positive PTLD post-allogeneic HCT after failure of rituximab-containing therapy.Bone marrow transplantation · 2024Article
- Article
- Review
- Third-party CMV- and EBV-specific T-cells for first viral reactivation after allogeneic stem cell transplant.Blood advances · 2022Article
- Blinatumomab induces complete response in refractory PTLD after hematopoietic cell transplantation.Blood advances · 2022Article
- An Unusual Presentation of Glandular Fever.Case reports in infectious diseases · 2022Article
- Clinical value of plasma and peripheral blood mononuclear cells Epstein-Barr Virus DNA dynamics on prognosis of allogeneic stem cell transplantation.Frontiers in cellular and infection microbiology · 2022Article
- Validation of a Post-Transplant Lymphoproliferative Disorder Risk Prediction Score and Derivation of a New Prediction Score Using a National Bone Marrow Transplant Registry Database.The oncologist · 2021Article
- Viral infections in lung transplantation.Journal of thoracic disease · 2021Review
- EBV-PTLD in a patient after haploidentical stem-cell transplantation with post-transplant cyclophosphamide.International journal of hematology · 2021Article
- Post-transplantation lymphoproliferative disorder after haematopoietic stem cell transplantation.Annals of hematology · 2021Review
- Epstein-Barr virus-positive lymphoproliferative disorder manifesting as pulmonary disease in a patient with acute myeloid leukemia: a case report.Journal of medical case reports · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
EBV-induced post transplantation lymphoproliferative disorder (EBV-PTLD) is a life-threatening complication after allogeneic hematopoietic cell transplantation. Profound T-cell depletion of the allograft represents a major risk factor for EBV-PTLD. With regard to the increasing use of alternative stem cell sources such as cord blood or purified haploidentical stem cell grafts both associated with impaired immune reconstitution, the frequent occurrence of EBV-PTLD demands particular vigilance on laboratory changes and early symptoms. Here we have summarized today's knowledge about EBV-PTLD in a comprehensive review explaining the underlying mechanisms of EBV-based transformation, EBV-PTLD development, clinical presentation, incidence, diagnosis, screening, therapy and prognosis. In this context, we emphasize on the necessity of regularly applied screening tools and pre-emptive treatment strategies including anti-CD20 Abs particularly in high-risk patients to avoid disease progression to malignant lymphoma. Although EBV-PTLD has always been associated with a high mortality rate, novel immunotherapeutic approaches such as the transfer of EBV-specific T cells nowadays offer improved chances of disease control even at late stages.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.